Follow-up for Alzheimer patients: European Alzheimer Disease Consortium position paper

Journal of Nutrition, Health and Aging

Volumn 14, Issue 2, 2010, Pages 121-130

  Nourhashemi F ^a,b   Olde Rikkert, M G ^c   Burns, A ^d   Winblad, B ^e   Frisoni, G B ^f   Fitten, J ^g   Vellas, B ^a,b  

^a CHU PURPAN   (France)

^b INSERM   (France)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e KAROLINSKA INSTITUTE   (Sweden)

^f IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^g VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Alzheimer; Caregiver; Follow up; Management; Treatment

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; CENTRAL NERVOUS SYSTEM AGENTS;

ALZHEIMER DISEASE; BODY WEIGHT; CAREGIVER; COGNITION; EUROPE; FALLING; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MOTOR DYSFUNCTION; NUTRITIONAL STATUS; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; AGED; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DISEASE COURSE; GERIATRIC ASSESSMENT; HEALTH CARE QUALITY; HEALTH STATUS; PATHOLOGY; QUALITY OF LIFE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM AGENTS; DISEASE PROGRESSION; EUROPE; FOLLOW-UP STUDIES; GERIATRIC ASSESSMENT; HEALTH STATUS; HUMANS; QUALITY OF HEALTH CARE; QUALITY OF LIFE;

EID: 77952307992     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-010-0023-z     Document Type: Review

References (218)

1. Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, von Strauss E, Winblad B. Dementia is the major cause of functional dependence in the elderly: 3-year followup data from a population-based study. Am J Public Health 1998;88:1452-1456.
2. Gill TM, Williams CS, Richardson ED, Berkman LF, Tinetti ME. A predictive model for ADL dependence in community-living older adults based on a reduced set of cognitive status items. J Am Geriatr Soc 1997;45:441-445.
3. Kalaria RN, Maestre GE, Arizaga R et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008;7:812-826.
4. Gattman R, Seleski M, editors. Diagnosis, management and treatment of dementia: a practical guide for physicians. Chicago, IL: American Medical Association; 1999: p. 1-47.
5. Reynish E, Cortes F, Andrieu S et al. The ICTUS Study: A Prospective longitudinal observational study of 1, 380 AD patients in Europe. Study design and baseline characteristics of the cohort. Neuroepidemiology 2007;29:29-38.
6. Nourhashémi F, Gillette-Guyonnet S, Andrieu S, Rolland Y, Ousset PJ, Vellas B and the PLASA Group. A randomised trial of the impact of a specific care plan in 1120 Alzheimer's patients (PLASA Study) over a two-year period: design and baseline data. J Nutr Health and Aging 2008;12:263-671.
7. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
8. Mattis S. Mental status examination for organic mental syndrome in the elderly patients. In: Geriatric psychiatry: a handbook for psychiatrists and primary care physicians. BellaL, Karasu TB (eds). Grune & Stratton, New York, 1976:77-101.
9. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
10. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
11. Cummings JL, Frank JC, Cherry D et al. Guidelines for managing Alzheimer's disease: part I. Assessment. Am Fam Physician 2002;65:2263-2272.
12. Rubin GD. The primary care of Alzheimer's disease. Am J Med Sci 2006;332:314-333.
13. Brooks JO 3rd, Kraemer HC, Tanke ED, Yesavage JA. The methodology of studying decline in Alzheimer's disease. J Am Geriatr Soc 1993;41:623-628.
14. Stern RG, Mohs RC, Davidson M et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-396.
15. Teri L, McCurry S, Edland S, Kukull W, Larson E. Cognitive decline in Alzheimer's disease: a longitudinal investigation of risk factors for accelerated decline. J Gerontol A Biol Sci Med Sci 1995;50 A: M49-M55.
16. Storandt M, Grant EA, Miller JP, Morris JC. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology 2002;59:1034-1041.
17. Atchison TB, Bradshaw M, Massman PJ. Investigation of profile difference between Alzheimer's disease patients declining at different rates: examination of baseline neuropsychological data. Arch Clin Neuropsychol 2004;19:1007-1015.
18. Clark CM, Sheppard L, Fillenbaum GG et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 1999;56:857-862.
19. Han L, Cole M, Bellavance F, McCusker J, Primeau F. Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis. Int Psychogeriatr 2000;12:231-247.
20. Cortes F, Nourhashémi F, Guérin O et al. Prognosis of Alzheimer's disease today: a two-year prospective study in 686 patients from the REAL-FR Study. Alzheimers Dement 2008;4:22-29.
21. Mortimer JA, Ebbitt B, Jun. SP, Finch MD. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 1992;42:1689-1696.
22. Mulnard RA, Cotman CW, Kawas C et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000;283:1007-1015.
23. Aisen PS, Davis KL, Berg JD et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000;54:588-593.
24. Wilson RS, Benett DA, Gilley DW, Beckett LA, Schneider JA, Evans DA. Progression of parkinsonian signs in Alzheimer's disease. Neurology 2000;54:1284-1289.
25. Neumann PJ, Araki SS, Arcelus A et al. Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD. Neurology 2001;57:957-964.
26. Doody RS, Massman P, Dunn JK. A method for estimating progression rates in Alzheimer disease. Arch Neurol 2001;58:449-454.
27. Capitani E, Cazzaniga R, Francescani A, Spinnler H. Cognitive deterioration in Alzheimer's disease: is the early course predictive of the later stages? Neurol Sci 2004;4:198-204.
28. Behl P, Stefurak TL, Black SE. Progress in clinical neurosciences: cognitive markers of progression in Alzheimer's disease. Can J Neurol Sci 2005;32:140-151.
29. Hansen RA, Gartlehner G, Kaufer DJ, et al. Drug class review on Alzheimer's drugs. RTI-UNC Evidence based Practice Center. Portland, OR: Oregon Health and Science University 2005; Available at: http://www.ohsu.edu/ drugeffectiveness/reports/final.cfm (accessed in november 2008).
30. Grimmer T, Kurz A. Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease: a systematic review. Drugs Aging 2006;23:957-67.
31. Geldmacher DS. Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care. Prim Care Companion J Clin Psychiatry 2007;9:113-121.
32. Cummings JL, Mackell J, Kaufer D. Behavioral effects of current Alzheimer's disease treatments: a descriptive review. Alzheimer's & dementia 2008;4:49-60.
33. Birks J. Cholinesterase inhibitors for Alzheimer's disease (Review). Cochrane Database Syst Rev 2006; (1): CD005593.
34. Katona C, Livingston G, Cooper C, Ames D, Brodaty H, Chiu E. International Psychogeriatric Association consensus statement on defining and measuring treatment benefits in dementia. Int Psychogeriatr 2007;19:345-354.
35. NICE: National Institute for Health and Clinical Excellence. Donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer's disease (amended); September 2007. Available at: http://www.nice.org. uk/guidance/index.jsp?action= download&o=36556.
36. Tinklenberg JR, Kraemer HC, Yaffe K et al. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice? Am J Geriatr Psychiatry 2007;15:953-960.
37. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000;10:195-203.
38. Doraiswamy PM, Krishnan KR, Anand R, et al. Long-term effects of rivastigmine in moderately severe Alzheimer's disease. Does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 2002;26:705-712.
39. Lyketsos CG, Reichman WE, Kershaw P, Zhu Y. Long-term outcomes of galantamine treatment in patients with Alzheimer disease. Am J Geriatr Psychiatr 2004;12:473-482.
40. Irttilä T, Wilcock truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 2004;11:734-741.
41. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004;61:252-256.
42. Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005;59:473-477.
43. Livingston G, Katona C. How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatr Psychiatry 2000;15:203-207.
44. Fillit HM, Doody RS, Binaso K et al. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother 2006;4 Suppl A: S9-S24.
45. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-146.
46. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
47. Aerosa Sastre A, Sherriff F, McShane R. Memantine for dementia (Review). Cochrane Database Syst Rev. 2005;3: CD003154.
48. Peskind ER, Potkin SG, Pomara N et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006;14:704-715.
49. Pomara N, Ott BR, Peskind E, Resnick EM. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Alzheimer Dis Assoc Disord 2007;21:60-64.
50. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; CD003154.
51. Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother 2008;42:32-38.
52. Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Postgrad Med 2005; Spec No: 6-22.
53. Zarowitz BJ, Stefanacci R, Hollenack K, O'Shea T, Gruber J, Tangalos EG. The application of evidence-based principles of care in older persons (issue 5): Alzheimer's disease. J Am Med Dir Assoc 2007;8:183-193.
54. Patterson CJ, Gauthier S, Bergman H et al. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. CMAJ 1999;160(Suppl): S1-15.
55. Lyketsos CG, Colenda CC, Beck C et al.; Task Force of American Association for Geriatric Psychiatry. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006;14:561-572.
56. Cummings JL, Frank JC, Cherry D et al. Guidelines for managing Alzheimer's disease: part II. Treatment. Am Fam Physician 2002;65:2525-2234.
57. Katona C, Livingston G, Cooper C, Ames D, Brodaty H, Chiu E. International Psychogeriatric Association consensus statement on defining and measuring treatment benefits in dementia. Int Psychogeriatr 2007;19:345-354.
58. Feil DG, MacLean C, Sultzer D. Quality indicators for the care of dementia in vulnerable elders. J Am Geriatr Soc 2007, 55: S293-S301.
59. Practice guideline for treatment of patients with Alzheimer's disease and other dementias of late life. Am Psychiatric Association. Am J Psychiatry 1997;154(5 Suppl): 1-39.
60. Schulz R, Beach SR. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA 1999;282:2215-2219.
61. Schulz R, Martire LM. Family caregiving of persons with dementia: prevalence, health effects, and support strategies. Am J Geriatr Psychiatry 2004;12:240-249.
62. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
63. Sultzer DL, Levin HS, Mahler et al. Assessment of cognitive, psychiatric, and behavioural disturbances in patients with dementia: The Neurobehavioral Rating Scale. J Am Geriatr Soc 1992;40:549-555.
64. Cohen-Mansfield J. Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument. Int Psychogeriatr 1996;8 Suppl 3:309-315.
65. Reisberg B, Auer SR, Monteiro IM. Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale. Int Psychogeriatr 1996;8 Suppl 3:301-308.
66. Grossberg GT, Desai AK. Management of Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2003;58:331-353.
67. Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 1996; Suppl 3:497-500.
68. Opie J, Rosewarne R, O'Connor DW. The efficacy of psychosocial approaches to behaviour disorders in dementia: a systematic literature review. Aust N Z J Psychiatry 1999;33:789-99.
69. Howard R, Ballard C, O'Brien J, Burns A; UK and Ireland Group for Optimization of Management in dementia. Guidelines for the management of agitation in dementia. Int J Geriatr Psychiatry 2001;16:714-717.
70. Callahan CM, Boustani MA, Unverzagt FW et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA 2006;295:2148-2157.
71. Waldemar G, Dubois B, Emre M et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14: e1-26.
72. Hogan DB, Bailey P, Carswell A, Clarke B et al. Management of mild to moderate Alzheimer's disease and dementia. Alzheimer's & Dementia 2007;3:355-384.
73. Guerriero Austrom M, Damush TM, Hartwell CW et al. Development and implementation of nonpharmacologic protocols for the management of patients with Alzheimer's disease and their families in a multiracial primary care setting. Gerontologist 2004;44:548-553.
74. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006; CD003476.
75. Herrmann N, Lanctôt KL. Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease. Can J Psychiatry 2007;52:630-646.
76. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th edition). American Psychiatric Association, Washington, 1994.
77. Andersen CK, Wittrup-Jensen KU, Lolk A, Andersen K, Kragh-Sorensen P. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life Outcomes 2004;2:52.
78. Galasko D, Corey-Bloom J, Thal LJ. Monitoring progression in Alzheimer's disease. J Am Geriatr Soc 1991;39:932-941.
79. Green CR, Mohs RC, Schmeidler J, Aryan M, Davis KL. Functional decline in Alzheimer's disease: a longitudinal study. J Am Geriatr Soc 1993;41:654-661.
80. Brickman AM, Riba A, Bell K, Marder K, Albert M, Brandt J, Stern Y. Longitudinal Assessment of patient dependence in Alzheimer disease. Arch Neurol 2002;59:1304-1308.
81. Byrne LM, Wilson PM, Bucks RS, Hughes AO, Wilcock GK. The sensitivity to change over time of the Bristol Activities of Daily Living Scale in Alzheimer's disease. Int J Geriatr Psychiatry 2000;15:656-661.
82. Holmes C, Lovestone S. Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Ageing 2003;32:200-204.
83. Stavitsky K, Brickman AM, Scarmeas N et al. The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease. Arch Neurol 2006;63:1450-1456.
84. Mohs RC, Schmeidler J, Aryan M. Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. Stat Med 2000;19:1401-1409.
85. Feldman H, Schulzer M, Wang S, Tuokko H, Beatie BL. The Functional Rating Scale in AD assessment: a longitudinal Study. In Research advances in Alzheimer's disease and related disorders 1995. Edited by K. Iqbal, JA Mortimer, B. Winblad, HM Wisniewski.
86. Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of neurology. Neurology 2001;56:1154-1166.
87. Gitlin LN, Winter L, Dennis MP, Corcoran M, Schinfeld S, Hauck WW. Strategies used by families to simplify tasks for individuals with Alzheimer's disease and related disorders: psychometric analysis of the Task Management Strategy Index (TMSI). Gerontologist 2002;42:61-69.
88. Alzheimer A. Über eine eigenartige erkramkung der hirnreinde. Allg Zeitschrf Psych 1970; vol 64, p. 146-148.
89. White H, Pieper C, Schmader K, Fillenbaum G. Weight change in Alzheimer's disease. J Am Geriatr Soc 1996;44:1232-1234.
90. Gillette-Guyonnet S, Nourhashemi F, Andrieu S et al. Weight loss in Alzheimer's disease. Am J Clin Nutr 2000;71:613S-618S.
91. Guerin O, Andrieu S, Schneider SM et al. Different modes of weight loss in Alzheimer disease: a prospective study of 395 patients. Am J Clin Nutr 2005;82:435-441.
92. Berlinger WG, Potter JF. Low body mass index in demented outpatients. J Am Geriatr Soc 1991;39:973-978.
93. Grundman M, Corey-Bloom J, Jernigan T, Archibald S, Thal LJ. Low body weight in Alzheimer's disease is associated with mesial temporal cortex atrophy. Neurology 1996;46:1585-1591.
94. Donaldson KE, Carpenter WH, Toth MJ, Goran MI, Newhouse P, Poehlman ET. No evidence for a higher resting metabolic rate in noninstitutionalized Alzheimer's disease patients. J Am Geriatr Soc 1996;44:1232-1234.
95. Billington CJ, Briggs JE, Harker S, GRACE M, LEVINE AS. Neuropetpide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism. Am J Physiol 1994;266: R1765-770.
96. Blandford G, Watkins LB et al. Assessing abnormal feeding behavior in dementia: a taxonomy an initial findings in Research and Practice in Alzheimer's Disease New York Springer Publishing company pp 47-64; 1998.
97. Hickson M. Malnutrition and ageing. Postgrad Med J 2006;82:2-8.
98. Hawkes C. Olfaction in neurodegenerative disorder. Adv Otorhinolaryngol 2006;63:133-151.
99. Shatenstein B, Kergoat MJ, Reid I. Poor nutrient intakes during 1-year follow-up with community-dwelling older adults with early-stage Alzheimer dementia compared to cognitively intact matched controls. J Am Diet Assoc 2007;107:2091-2099.
100. Razay G., Gordon K. W. Hyperinsulinaemia and Alzheimer's disease. Age Ageing 1994;23:396-399.
101. Vanhanen M, Kivipelto M, Koivisto K et al. ApoE4 is associated with weight loss in women with Alzheimer's disease. Neurology 2001;56:655-659.
102. Vellas B, Lauque S, Gillette-Guyonnet S et al. Impact of nutritional status on the evolution of Alzheimer's disease and on response to acetylcholinesterase inhibitor treatment. J Nutr Health Aging 2005;9:75-80
103. Andrieu S, Reynish W, Nourhashemi F et al. Nutritional risk factors for institutional placement in Alzheimer's disease after one year follow-up. J Nutr Health Aging 2001;5:113-117.
104. White H, Pieper C, Schmader K. The Association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc 1998;46:1223-1227.
105. Ousset PJ, Nourhashemi F, Reynish E, Vellas B. Nutritional status is associated with disease progression in very mild Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22:66-71.
106. Keller HH, Gibbs AJ, Boudreau LD, Goy RE, Pattillo MS, Brown HM. Prevention of weight loss in dementia with comprehensive nutritional treatment. J Am Geriatr Soc 2004;52:1216-1217.
107. Carver AD, Dobson AM. Effects of dietary supplementation of elderly demented hospital residents. J Hum Nutr Diet 1995;8:389-394.
108. Rivière S, Gillette-Guyonnet S, Voisin T et al. A nutritional education program could prevent weight loss and slow cognitive decline in Alzheimer's Disease. J Nutr Health Aging 2001;5:295-299.
109. Gil Gregorio P, Ramirez Diaz SP, Ribera Casado JM; DEMENU group. Dementia and Nutrition. Intervention study in institutionalized patients with Alzheimer disease. J Nutr Health Aging 2003;7:304-308.
110. Lauque S, Arnaud-Battandier F, Gillette S et al. Improvement of weight and fat-free mass with oral nutritional supplementation in patients with Alzheimer's disease at risk of malnutrition: a prospective randomized study. J Am Geriatr Soc 2004;52:1702-1707.
111. Young KW, Greenwood CE, van Reekum R, Binns MA. Providing nutrition supplements institutionalized seniors with probable Alzheimer's disease is least beneficial to those with low body weight status. J Am Geriatr Soc 2004;52:1305-1312.
112. Gillette Guyonnet S, Abellan Van Kan G, Alix E et al. IANA (International Academy on Nutrition and Aging) Expert Group: weight loss and Alzheimer's disease. J Nutr Health Aging 2007;11:38-48.
113. Finucane TE, Christmas C, Travis K. Tube feeding in patients with advanced dementia: a review of the incidence. JAMA 1999;282:1365-1370.
114. Mitchell SL, Kiely DK, Lipsitz LA. The risk factors and impact on survival of feeding tube placement in nursing home residents with severe cognitive impairment. Arch Intern Med 1997;157:327-332.
115. Monteleoni C, Clark E. Using rapid-cycle quality improvement methodology to reduce feeding tubes in patients with advanced dementia: before and after study. BMJ 2004;329:491-494.
116. Vellas B, Guigoz Y, Garry P et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state in elderly patients. Nutrition 1999;15:116-122.
117. Sieber CC. Nutritional screening tools-How does the MNA compare? Proceedings of the session held in Chicago May 2-3, 2006 (15 Years of Mini Nutritional Assessment). J Nutr Health Aging 2006;10:488-492; discussion 492-494.
118. Gil Gregorio P, Ramirez Diaz SP, Ribera Casado JM; Demenu group. Dementia and Nutrition. Intervention study in institutionalized patients with Alzheimer disease. J Nutr Health Aging 2003;7:304-308.
119. Mc Khann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: report pf the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;36:939-944.
120. Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ, Buschke H. Abnormality of gait as a predictor of non-Alzheimer's dementia. N Engl J Med 2002;28:1761-1768.
121. Pettersson AF, Engardt M, Wahlund LO. Activity level and balance in subjects with mild Alzheimer's disease. Dement Geriatr Cogn Disord 2002;13:213-216.
122. Pettersson AF, Olsson E, Wahlund LO. Motor function in subjects with mild cognitive impairment and early Alzheimer's disease. Dement Geriatr Cogn Disord 2005;19:299-304.
123. Guerini F, Frisoni GB, Marre A, Turco R, Bellelli G, Trabucchi M. Subcortical vascular lesions predict falls at 12 months in elderly patients discharged from a rehabilitation ward. Arch Phys Med Rehabil 2008;89:1522-1527.
124. Alexander NB, Mollo JM, Giordani B et al. Maintenance of balance, gait patterns, and obstacle clearance in Alzheimer's disease. Neurology 1995;45:908-914.
125. Wilson RS, Gilley DW, Bennett DA, Beckett LA, Evans DA. Person-specific paths of cognitive decline in Alzheimer's disease and their relation to age. Psychol Aging 2000;15:18-28.
126. Camicioli R, Bouchard T, Licis L. Dual-tasks and walking fast: Relationship to extrapyramidal signs in advanced Alzheimer disease. J Neurol Sci 2006;248:205-209.
127. Della Sala S, Spinnler H, Venneri A. Walking difficulties in patients with Alzheimer's disease might originate from gait apraxia. J Neurol Neurosurg Psychiatry 2004;75:196-201.
128. Zadikoff C, Lang AE. Apraxia in movement disorders Brain 2005;128:1480-1497.
129. O'Keeffe ST, Kazeem H, Philpott RM, Playfer JR, Gosney M, Lye M. Gait disturbance in Alzheimer's disease: a clinical study. Age Ageing 1996;25:313-316.
130. Chen JY, Stern Y, Sano M, Mayeux R. Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer's disease. Arch Neurol 1991;48:1141-1143.
131. Sheridan PL, Solomont J, Kowall N, Hausdorff JM. Influence of executive function on locomotor function: divided attention increases gait variability in Alzheimer's disease. J Am Geriatr Soc 2003;51:1633-1637.
132. Manckoundia P, Mourey F, Pfitzenmeyer P, Papaxanthis C. Comparison of motor strategies in sit-to-stand and back-to-sit motions between healthy and Alzheimer's disease elderly subjects. Neuroscience 2006;137:385-392.
133. Goldman WP, Baty JD, Buckles VD, Sahrmann S, Morris JC. Motor dysfunction in mildly demented AD individuals without extrapyramidal signs. Neurology 1999;53:956-962.
134. Webster KE, Merory JR, Witter JE. Gait variability in community dwelling adults with Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:37-40.
135. Lord SR, Clark RD. Simple physiological and clinical tests for the accurate prediction of falling in older people. Gerontology 1996;42:199-203.
136. Myers AH, Baker SP, Van Natta ML, Abbey H, Robinson EG. Risk factors associated with falls and injuries among elderly institutionalized persons. Am J Epidemiol 1991;133:1179-1190.
137. Nevitt MC, Cummings SR, Hudes ES. Risk factors for injurious falls: a prospective study. J Gerontol 1991;46: M164-M170.
138. Tinetti ME, Doucette J, Claus E, Marottoli R. Risk factors for serious injury during falls by older persons in the community. J Am Geriatr Soc 1995;43:1214-1221.
139. Morris JC, Rubin EH, Morris EJ, Mandel SA. Senile dementia of the Alzheimer's type: an important risk factor for serious falls. J Gerontol 1987;42:412-417.
140. Jantti PO, Pyykko VI, Hervonen AL. Falls among elderly nursing home residents. Public Health 1993;107:89-96.
141. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988;319:1701-1707.
142. van Dijk PT, Meulenberg OG, van de Sande HJ, Habbema JD. Falls in dementia patients. Gerontologist 1993;33:200-204.
143. Melton LJ 3rd, Beard CM, Kokmen E, Atkinson EJ, O'Fallon WM. Fracture risk in patients with Alzheimer's disease. J Am Geriatr Soc 1994;42:614-619.
144. Johansson C, Skoog I. A population-based study on the association between dementia and hip fractures in 85-year olds. Aging (Milano) 1996;8:189-196.
145. Buchner DM, Larson EB. Falls and fractures in patients with Alzheimer-type dementia. JAMA 1987;257:1492-1495.
146. Guo Z, Wills P, Viitanen M, Fastbom J, Winbladt B. Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 years old: a community-based prospective study. Am J Epidemiol 1998;148:887-892.
147. Schwartz AV, Kelsey JL, Sidney S, Grisso JA. Characteristics of falls and risk of hip fracture in elderly men. Osteoporos Int 1998;8:240-246.
148. Weller I, Schatzker J. Hip fractures and Alzheimer's disease in elderly institutionalized Canadians. Ann Epidemiol 2004;14:319-324.
149. Heruti RJ, Lusky A, Barell V, Ohry A, Adunsky A. Cognitive status at admission: does it affect the rehabilitation outcome of elderly patients with hip fracture? Arch Phys Med Rehabi 1999;80:432-436.
150. Beloosesky Y, Grinblat J, Epelboym B, Weiss A, Grosman B, Hendel D. Functional gain of hip fracture patients in different cognitive and functional groups. Clin Rehabil 2002;16:321-328.
151. Goldstein FC, Strasser DC, Woodard JL, Roberts VJ. Functional outcome of cognitively impaired hip fracture patients on a geriatric rehabilitation unit. J Am Geriatr Soc 1997;45:35-42.
152. Rolland Y, Pillard F, Lauwers-Cances V, Busquere F, Vellas B, Lafont C. Rehabilitation outcome of elderly patients with hip fracture and cognitive impairment. Disabil Rehabil 2004;26:425-431.
153. Thompson P, Jones C, Dawson A, Thomas P, Villar T. An in-service evaluation of hip protector use in residential homes. Age Ageing 2005;34:52-56.
154. Sato Y, Kanoko T, Satoh K, Iwamoto J. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med 2005;165:1737-1742.
155. Cree M, Soskolne CL, Belseck E et al. Mortality and institutionalization following hip fracture. J Am Geriatr Soc 2000;48:283-288.
156. Oleske DM, Wilson RS, Bernard BA, Evans DA, Terman EW. Epidemiology of injury in people with Alzheimer's disease. J Am Geriatr Soc 1995;43:741-746.
157. Rolland Y, Pillard F, Reynish E, Thomas D, Andrieu S, Rivière D, Vellas B. Exercise Program in Nursing Home Residents with Alzheimer's disease. A One-Year Randomized Controlled Trial. J Am Geriatr Soc 2007;55:158-165.
158. Shaw FE, Bond J, Richardson DA, Dawson P, Steen IN, McKeith IG, Kenny RA. Multifactorial intervention after a fall in older people with cognitive impairment and dementia presenting to the accident and emergency department: randomised controlled trial. BMJ 2003;326:73.
159. Teri L, Gibbons LE, McCurry SM et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 2003;290:2015-2022.
160. Buettner LL. Falls prevention in dementia population. Provider 2002;28:41-43.
161. Cott CA, Dawson P, Sidani S, Wells D. The effects of a walking/talking program on communication, ambulation, and functional status in residents with Alzheimer disease. Alzheimer Dis Assoc Disord 2002;16:81-87.
162. Frances T. The effect of regular exercise on muscle strength and functional abilities of late stage Alzheimer's disease. Va Nurses Today 1995;3:25-26.
163. Pomeroy VM, Warren CM, Honeycombe C et al. Mobility and dementia: is physiotherapy treatment during respite care effective? Int J Geriatr Psychiatry 1999;14:389-397.
164. Pomeroy VM. The effect of physiotherapy input on mobility skills of elderly people with severe dementing illness. Clin Reahabil 1993;7:163-170.
165. Tappen RM, Roach KE, Applegate EB, Stowell P. Effect of a combined walking and conversation intervention on functional mobility of nursing home residents with Alzheimer disease. Alzheimer Dis Assoc Disord 2000;14:196-201.
166. Toulotte C, Fabre C, Dangremont B, Lensel G, Thevenon A. Effects of physical training on the physical capacity of frail, demented patients with a history of falling: a randomised controlled trial. Age Ageing 2003;32:67-73.
167. Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc 1986;34:119-126.
168. Vellas BJ, Wayne SJ, Romero L, Baumgartner RN, Rubenstein LZ, Garry PJ. Oneleg balance is an important predictor of injurious falls in older persons. J Am Geriatr Soc 1997;45:735-738.
169. Y Rolland, G Abellan van Kan, B Vellas. Physical activity and Alzheimer's disease. J Am Med Dir Assoc 2008;9:390-405.
170. Mittelman MS, Ferris SH, Shulman E, Steinberg G, Levin B. A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. JAMA 1996;276:1725-1731
171. Marriott A, Donaldson C, Tarrier N, Burns A. Effectiveness of cognitive-behavioural family intervention in reducing the burden of care in caregivers of patients with Alzheimer's disease. Br J Psychiatry 2000;176:557-562.
172. Mittelman MS, Ferris SH, Steinberg G et al. An intervention that delays institutionalization of Alzheimer's disease patients: treatment of spouse-caregivers. Gerontologist 1993;33:730-740.
173. Mittelman MS, Haley WE, Clay OJ, Roth DL. Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease. Neurology 2006;67:1592-1599.
174. Mittelman MS, Roth DL, Haley WE, Zarit SH. Effects of a caregiver intervention on negative caregiver appraisals of behavior problems in patients with Alzheimer's disease: results of a randomized trial. J Gerontol B Psychol Sci Soc Sci 2004;59: P27-P34.
175. Mohide EA, Pringle DM, Streiner DL, Gilbert JR, Muir G, Tew M. A randomized trial of family caregiver support in the home management of dementia. J Am Geriatr Soc 1990;38:446-454.
176. Nobili A, Riva E, Tettamanti M et al. The effect of a structured intervention on caregivers of patients with dementia and problem behaviors: a randomized controlled pilot study. Alzheimer Dis Assoc Disord 2004;18:75-82.
177. Brodaty H, Gresham M. Effect of a training programme to reduce stress in caregivers of patients with dementia. BMJ 1989;299:1375-1379.
178. Burns R, Nichols LO, Martindale-Adams J, Graney MJ, Lummus A. Primary care interventions for dementia caregivers: 2-year outcomes from the REACH study. Gerontologist 2003;43:547-555.
179. Thompson C, Spilsbury K. Support for caregivers of people with Alzheimer's type dementia. Cochrane Database Syst Rev 2007; CD000454.
180. Sörensen S, Pinquart M, Duberstein P. How effective are interventions with caregivers? An updated meta-analysis. Gerontologist 2002;42:356-372.
181. Nichols LO, Chang C, Lummus A et al.; for the Resources for Enhancing Alzheimer's Caregivers Health II Investigators. The Cost-Effectiveness of a Behavior Intervention with Caregivers of Patients with Alzheimer's Disease. J Am Geriatr Soc 2008;56:413-420.
182. Martikainen J, Valtonen H, Pirttilä T. Potential cost-effectiveness of a family-based program in mild Alzheimer's disease patients. Eur J Health Econ 2004;5:136-142.
183. Vickrey BG, Mittman BS, Connor KI et al. The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial. Ann Intern Med 2006;145:713-726
184. von Känel R, Dimsdale JE, Mills PJ et al. Effect of Alzheimer caregiving stress and age on frailty markers interleukin-6, C-reactive protein, and D-dimer. J Gerontol A Biol Sci Med Sci 2006;61:963-969.
185. Small GW, Rabins PV, Barry PP et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-1371.
186. Wolf-Klein G, Pekmezaris R, Chin L, Weiner J. Conceptualizing Alzheimer's disease as a terminal medical illness. Am J Hosp Palliat Care 2007;24:77-82.
187. Volicer L. Management of severe Alzheimer's disease and end-of-life issues. Clin Geriatr Med 2001;17:377-391.
188. Vellas B, Gauthier S, Allain H et al. Consensus statement on dementia of Alzheimer type in the severe stage. J Nutr Health Aging 2005;9:330-338.
189. Kim KY, Yeaman PA, Keene RL. End-of-life care for persons with Alzheimer's disease. Psychiatr Serv 2005;56:139-141.
190. Koopmans RT, van der Sterren KJ, van der Steen JT. The 'natural' endpoint of dementia: death from cachexia or dehydration following palliative care? Int J Geriatr Psychiatry 2007;22:350-355
191. Volicer L. Goals of care in advanced dementia: quality of life, dignity and comfort. J Nutr Health Aging 2007;11:481.
192. Van der Steen JT, Ooms ME, Mehr DR, Van der Wal G, Ribbe MW. Severe dementia and adverse outcomes of nursing home-acquired pneumonia: evidence for mediation by functional and pathophysiological decline. J Am Geriatr Soc 2002;50:439-448.
193. Kalia M. Dysphagia and aspiration pneumonia in patients with Alzheimer's disease. Metabolism 2003;52 Suppl 2:36-38.
194. Wada H, Nakajoh K, Satoh-Nakagawa T et al. Risk factors of aspiration pneumonia in Alzheimer's disease patients. Gerontology 2001;47:271-276.
195. Van der Steen JT, Ooms ME, Van der Wal G, Ribbe MW. Withholding or starting antibiotic treatment in patients with dementia and pneumonia: prediction of mortality with physicians' judgment of illness severity and with specific prognostic models. Med Decis Making 2005;25:210-221.
196. Sampson EL, Ritchie CW, Lai R, Raven PW, Blanchard MR. A systematic review of the scientific evidence for the efficacy of a palliative care approach in advanced dementia. Int Psychogeriatr 2005;17:31-40.
197. Kettl P. Helping families with end-of-life care in Alzheimer's disease. J Clin Psychiatry 2007;68:445-450.
198. Nourhashémi F, Gillette S, Andrieu S. Managing Alzheimer's disease: global care and support program. Rev Prat 2005;55:1903-1911.
199. California Workgroup on guidelines for Alzheimer's Disease Management. Guidelines for Alzheimer's disease management. 2002.
200. Christensen MD, White HK. Dementia assessment and management. J Am Med Dir Assoc 2007;8(3 Suppl 2): e89-98.
201. Small GW, McDonnell DD, Brooks RL, Papadopoulos G. The impact of symptom severity on the cost of Alzheimer's disease. J Am Geriatr Soc 2002;50:321-327.
202. Balardy L, Voisin T, Cantet C, Vellas B; REAL. FR Group. Predictive factors of emergency hospitalisation in Alzheimer's patients: results of one-year follow-up in the REAL. FR Cohort. J Nutr Health Aging 2005;9:112-116.
203. Nourhashémi F, Andrieu S, Sastres N et al. Descriptive analysis of emergency hospital admissions of patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2001;15:21-25.
204. Zhao Y, Kuo TC, Weir S, Kramer MS, Ash AS. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. BMC Health Serv Res 2008;8:108.
205. Torian L, Davidson E, Fulop G, Sell L, Fillit H. The effect of dementia on acute care in a geriatric medical unit. Int Psychogeriatr 1992;4:231-239.
206. Lyketsos CG, Sheppard JM, Rabbins PV et al. Dementia hospitalisation and psychiatry. Am J Psychiatry 2000;157:704-707.
207. Gillick MR, Serrell NA, Gillick LS. Adverse consequences of hospitalization in the elderly. Soc Sci Med 1982;16:1033-1038.
208. Cornette P, Swine C, Malhomme B, Gillet JB, Meert P, D'Hoore W. Early evaluation of the risk of functional decline following hospitalization of older patients: development of a predictive tool. Eur J Public Health 2006;16:203-208.
209. Hinton L, Franz CE, Reddy G, Flores Y, Kravitz RL, Barker JC. Practice constraints, behavioral problems, and dementia care: primary care physicians' perspectives. J Gen Intern Med 2007;22:1487-1492.
210. Bosenquet N, May J, Johnson N. Alzheimer's disease in the UK: burden of the disease and future care. Health policy review number 12. London: Imperial College of Science and Technologie, 1998.
211. Hill JW, Futterman R, Duttagupta S, Mastey V, Lloyd JR, Fillit HM. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology 2002;58:62-70.
212. Herrmann N, Gautier S, Lysy PG. Clinical practice guideline for severe Alzheimer's disease. Alzheimer's & Dementia 2007;3:385-397.
213. Galasko D, Benett D, Sano M et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alz Dis Assoc Dis 1997;11: S33-S39.
214. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914-919.
215. Gelinas I, Gauthier L, McIntyre Mn, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: The Disability Assessment for Dementia. Am J Occup Ther 1999;53:471-481.
216. Reisberg B. Functional Assessment Staging (FAST). Psychopharmacol Bull 1980;24:653-659.
217. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
218. Schmitt FA, Ashford W, Ernesto C et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 Suppl 2: S51-S56.